TRIM32 controls timely cell cycle exit in muscular differentiation through c-Myc down-regulation

Article activity feed

1. 

   Review Commons

   Dec 11, 2025

   Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Reply to the reviewers

   Reviewer #1 (Evidence, reproducibility and clarity (Required)):

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases.

   We thank the Reviewer for appreciating our work and for their valuable suggestions to improve our manuscript. We have carefully addressed some of the …

   Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Reply to the reviewers

   Reviewer #1 (Evidence, reproducibility and clarity (Required)):

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases.

   We thank the Reviewer for appreciating our work and for their valuable suggestions to improve our manuscript. We have carefully addressed some of the concerns raised, as detailed here, while others, which require more experimental efforts, will be addressed as detailed in the Revision Plan.

   In my opinion, a few aspects would improve the manuscript. Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studies investigating whether Tim32 binds directly to c-Myc RNA. Moreover, although possibly beyond the scope of this study, an unbiased screening of RNA species binding to Trim32 would be informative. Authors’ response. This point will be addressed as detailed in the Revision Plan

   If possible, studies in which the overexpression of different mutants presenting specific altered functional domains (NHL domain known to bind RNAs and Ring domain reportedly involved in protein ubiquitination) would be used to test if they are capable or incapable of rescuing the reported alteration of Trim32 KO cell lines in c-Myc expression and muscle maturation.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   An optional aspect that might be interesting to explore is whether the alterations in c-Myc expression observed in C2C12 might be replicated with primary myoblasts or satellite cells devoid of Trim32.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   I also have a few minor points to highlight:

   • • It is unclear if the differences highlighted in graphs 5G, EV5D, and EV5E are statistically significant.*

   Authors’ response. We thank the Reviewer for raising this point. We now indicated the statistical analyses performed on the data presented in the mentioned figures (according also to a point of Reviewer #3). According to the conclusion that Trim32 is necessary for proper regulation of c-Myc transcript stability, using 2-way-ANOVA, the data now reported as Figure 5G show the statistically significant effect of the genotype at 6h (right-hand graph) but not at D0 (left-hand graph). In the graphs of Fig. EV5 D and E at D0 no significant changes are observed whereas at 6h the data show significant difference at the 40 min time point. We included this info in the graphs and in the corresponding legends.

   - On page 10, it is stated that c-Myc down-regulation cannot rescue KO myotube morphology fully nor increase the differentiation index significantly, but the corresponding data is not shown. Could the authors include those quantifications in the manuscript?

   Authors’ response. As suggested, we included the graph showing the differentiation index upon c-Myc silencing in the Trim32 KO clones and in the WT clones, as a novel panel in Figure 6 (Fig. 6D). As already reported in the text, a partial recovery of differentiation index is observed but the increase is not statistically significant. In contrast, no changes are observed applying the same silencing in the WT cells. Legend and text were modified accordingly.

   Reviewer #1 (Significance (Required)):

   *The manuscript offers several strengths. It provides novel mechanistic insight by identifying a previously unrecognized role for Trim32 in regulating c-Myc mRNA stability during the onset of myogenic differentiation. The study is supported by a robust methodology that integrates CRISPR/Cas9 gene editing, transcriptomic profiling, flow cytometry, biochemical assays, and rescue experiments using siRNA knockdown. Furthermore, the work has a disease relevance, as it uncovers a mechanistic link between Trim32 deficiency and impaired myogenesis, with implications for the pathogenesis of LGMDR8. *

   • At the same time, the study has some limitations. The findings rely exclusively on the C2C12 myoblast cell line, which may not fully represent primary satellite cell or in vivo biology. The functional rescue achieved through c-Myc knockdown is only partial, restoring Myogenin expression but not the full differentiation index or morphology, indicating that additional mechanisms are likely involved. Although evidence supports a role for Trim32 in mRNA destabilization, the precise molecular partners-such as RNA-binding activity, microRNA involvement, or ligase function-remain undefined. Some discrepancies with previous studies, including Trim32-mediated protein degradation of c-Myc, are acknowledged but not experimentally resolved. Moreover, functional validation in animal models or patient-derived cells is currently lacking. Despite these limitations, the study represents an advancement for the field. It shifts the conceptual framework from Trim32's canonical role in protein ubiquitination to a novel function in RNA regulation during myogenesis. It also raises potential clinical implications by suggesting that targeting the Trim32-c-Myc axis, or modulating c-Myc stability, may represent a therapeutic strategy for LGMDR8. This work will be of particular interest to muscle biology researchers studying myogenesis and the molecular basis of muscle disease, RNA biology specialists investigating post-transcriptional regulation and mRNA stability, and neuromuscular disease researchers and clinicians seeking to identify new molecular targets for therapeutic intervention in LGMDR8. *
   • The Reviewer expressing this opinion is an expert in muscle stem cells, muscle regeneration, and muscle development.*

   Reviewer #2 (Evidence, reproducibility and clarity (Required)):

   *Summary: *

   • In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic signaling in the Trim32 KO cells, leading to a disruption of myotube formation in-vitro. Interestingly, while previous studies have focused on Trim32's role in protein ubiquitination and degradation of c-Myc, the authors provide evidence that Trim32-regulation of c-Myc occurs at the level of mRNA stability. The authors show that the sustained c-Myc expression in Trim32 knockout cells disrupts the timely expression of key myogenic factors and interferes with critical withdrawal of myoblasts from the cell cycle required for myotube formation. Overall, the study offers a new insight into how Trim32 regulates early myogenic progression and highlights a potential therapeutic target for addressing the defects in muscular regeneration observed in LGMDR8.*

   We thank the Reviewer for valuing our work and for their appreciated suggestions to improve our manuscript. We have carefully addressed some of the concerns raised as detailed here, while others, which require more laborious experimental efforts, will be addressed as reported in the Revision Plan.

   Major Comments:

   The work is a bit incremental based on this:

   *https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030445 *

   • And this:*

   *https://www.nature.com/articles/s41418-018-0129-0 *

   • To their credit, the authors do cite the above papers.*

   Authors’ response. We thank the Reviewer for this careful evaluation of our work against the current literature and for recognising the contribution of our findings to the understanding of myogenesis complex picture in which the involvement of Trim32 and c-Myc, and of the Trim32-c-Myc axis, can occur at several stages and likely in narrow time windows along the process, thus possibly explaining some reports inconsistencies.

   The authors do provide compelling evidence that Trim32 deficiency disrupts C2C12 myogenic differentiation and sustained c-Myc expression contributes to this defective process. However, while knockdown of c-Myc does restore Myogenin levels, it was not sufficient to normalize myotube morphology or differentiation index, suggesting an incomplete picture of the Trim32-dependent pathways involved. The authors should qualify their claim by emphasizing that c-Myc regulation is a major, but not exclusive, mechanism underlying the observed defects. This will prevent an overgeneralization and better align the conclusions with the author's data.

   Authors’ response. We agree with the Reviewer and we modified our phrasing that implied Trim32-c-Myc axis as the exclusive mechanism by explicitly indicated that other pathways contribute to guarantee proper myogenesis, in the Abstract and in Discussion.

   The Abstract now reads: “… suggesting that the Trim32–c-Myc axis may represent an essential hub, although likely not the exclusive molecular mechanism, in muscle regeneration within LGMDR8 pathogenesis.”

   The Discussion now reads: “Functionally, we demonstrated that c-Myc contributes to the impaired myogenesis observed in Trim32 KO clones, although this is clearly not the only factor involved in the Trim32-mediated myogenic network; realistically other molecular mechanisms can participate in this process as also suggested by our transcriptomic results.”

   The authors provide a thorough and well-executed interrogation of cell cycle dynamics in Trim32 KO clones, combining phosphor-histone H3 flow cytometry of DNA content, and CFSE proliferation assays. These complementary approaches convincingly show that, while proliferation states remain similar in WT and KO cells, Trim32-deficient myoblasts fail in their normal withdraw from the cell cycle during exposure to differentiation-inducing conditions. This work adds clarity to a previously inconsistent literature and greatly strengthens the study.

   Authors’ response. We thank the Reviewer for appreciating our thorough analyses on cell cycle dynamics in proliferation conditions and at the onset of the differentiation process.

   The transcriptomic analysis (detailed In the "Transcriptomic analysis of Trim32 WT and KO clones along early differentiation" section of Results) is central to the manuscript and provides strong evidence that Trim32 deficiency disrupts normal differentiation processes. However, the description of the pathway enrichment results is highly detailed and somewhat compressed, which may make it challenging for readers to following the key biological 'take-homes'. The narrative quickly moves across their multiple analyses like MDS, clustering, heatmaps, and bubble plots without pausing to guide the reader through what each analysis contributes to the overall biological interpretation. As a result, the key findings (reduced muscle development pathways in KO cells and enrichment of cell cycle-related pathways) can feel somewhat muted. The authors may consider reorganizing this section, so the primary biological insights are highlighted and supported by each of their analyses. This would allow the biological implications to be more accessible to a broader readership.

   Authors’ response. We thank the Reviewer for raising this point and apologise for being too brief in describing the data, leaving indeed some points excessively implicit. As suggested, we now reorganised this session and added the lists of enriched canonical pathways relative to WT vs KO comparisons at D0 and D3 (Fig. EV3B) as well as those relative to the comparison between D0 and D3 for both WT and Trim32 KO samples (Fig. EV3C), with their relative scores. We changed the Results section “Transcriptomic analysis of Trim32 WT and Trim32 KO clones along early differentiation*” *as reported here below and modified the legends accordingly.

   The paragraph now reads: “Based on our initial observations, the absence of Trim32 already exerts a significant impact by day 3 (D3) of C2C12 myogenic differentiation. To investigate how Trim32 influences early global transcriptional changes during the proliferative phase (D0) and early differentiation (D3), we performed an unbiased transcriptomic profiling of WT and Trim32 KO clones (Fig. 2A). Multidimensional Scaling (MDS) analysis revealed clear segregation of gene expression profiles based on both time of differentiation (Dim1, 44% variance) and Trim32 genotype (Dim2, 16% variance) (Fig. 2A). Likewise, hierarchical clustering grouped WT and Trim32 KO clones into distinct clusters at both timepoints, indicating consistent genotype-specific transcriptional differences (Fig. EV3A). Differentially Expressed Genes (DEGs) were detected in the Trim32 KO transcriptome relative to WT, at both D0 and D3. In proliferating conditions, 72 genes were upregulated and 189 were downregulated whereas at D3 of differentiation, 72 genes were upregulated and 212 were downregulated. Ingenuity Pathway Analysis of the DEGs revealed the top 10 Canonical Pathways displayed in Fig. EV3B as enriched at either D0 or D3 (Fig. EV3B). Several of these pathways can underscore relevant Trim32-mediated functions though most of them represent generic functions not immediately attributable to the observed myogenesis defects.

   Notably, the transcriptional divergence between WT and Trim32 KO cells is more pronounced at D3, as evidenced by a greater separation along the MSD Dim2 axis, suggesting that Trim32-dependent transcriptional regulation intensifies during early differentiation (Fig. 2A). Given our interest in the differentiation process, we therefore focused our analyses comparing the changes occurring from D0 to D3 in WT (WT D3 vs. D0) and in Trim32 KO (KO D3 vs. D0) RNAseq data.

   Pathway enrichment analysis of D3 vs. D0 DEGs allowed the selection of the top-scored pathways for both WT and Trim32 KO data. We obtained 18 top-scored pathways enriched in each genotype (-log(p-value) ³ 9 cut-off): 14 are shared while 4 are top-ranked only in WT and 4 only in Trim32 KO (Fig. EV3C). For the following analyses, we employed thus a total of 22 distinct pathways and to better mine those relevant in the passage from the proliferation stage to the early differentiation one and that are affected by the lack of Trim32, we built a bubble plot comparing side-by-side the scores and enrichment of the 22 selected top-scored pathways above in WT and Trim32 KO (Fig. 2B). A heatmap of DEGs included within these selected pathways confirms the clustering of the samples considering both the genotypes and the timepoints highlighting gene expression differences (Fig. 2C). These pathways are mainly related to muscle development, cell cycle regulation, genome stability maintenance and few other metabolic cascades.

   As expected given the results related to Figure 1, moving from D0 to D3 WT clones showed robust upregulation of key transcripts associated with the Inactive Sarcomere Protein Complex, a category encompassing most genes in the “Striated Muscle Contraction” pathway, while in Trim32 KO clones this pathway was not among those enriched in the transition from D0 to D3 (Fig. EV3C). Detailed analyses of transcripts enclosed within this pathway revealed that on the transition from proliferation to differentiation, WT clones show upregulation of several Myosin Heavy Chain isoforms (e.g., MYH3, MYH6, MYH8), α-Actin 1 (ACTA1), α-Actinin 2 (ACTN2), Desmin (DES), Tropomodulin 1 (TMOD1), and Titin (TTN), a pattern consistent with previous reports, while these same transcripts were either non-detected or only modestly upregulated in Trim32 KO clones at D3 (Fig. 2D). This genotype-specific disparity was further confirmed by gene set enrichment barcode plots, which demonstrated significant enrichment of these muscle-related transcripts in WT cells (FDR_UP = 0.0062), but not in Trim32 KO cells (FDR_UP = 0.24) (Fig. EV3D). These findings support an early transcriptional basis for the impaired myogenesis previously observed in Trim32 KO cells.

   In addition to differences in muscle-specific gene expression, we observed that also several pathways related to cell proliferation and cell cycle regulation were more enriched in Trim32 KO cells compared to WT. This suggests that altered cell proliferation may contribute to the distinct differentiation behavior observed in Trim32 KO versus WT (Fig. 2B). Given that cell cycle exit is a critical prerequisite for the onset of myogenic differentiation and considering that previous studies on Trim32 role in cell cycle regulation have reported inconsistent findings, we further examined cell cycle dynamics under our experimental conditions to clarify Trim32 contribution to this process”

   The work would be greatly strengthened by the conclusion of LGMDR8 primary cells, and rescue experiments of TRIM32 to explore myogenesis.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   Also, EU (5-ethynyl uridine) pulse-chase experiments to label nascent and stable RNA coupled with MYC pulldowns and qPCR (or RNA-sequencing of both pools) would further enhance the claim that MYC stability is being affected.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   "On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025)." Also address and discuss the following, as what is currently written is not entirely accurate: https://www.embopress.org/doi/full/10.1038/s44319-024-00299-z and https://journals.physiology.org/doi/prev/20250724-aop/abs/10.1152/ajpcell.00528.2025

   Authors’ response. We thank the Reviewer for bringing to our attention these two publications, that indeed, add important piece of data to recapitulate the in vivo complexity of c-Myc role in myogenesis. We included this point in our Discussion.

   The Discussion now reads: “On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025). Other reports, instead, demonstrated the implication of c-Myc periodic pulses, mimicking resistance-exercise, in muscle growth, a role that cannot though be observed in our experimental model (Edman et al., 2024; Jones et al., 2025).”

   Minor Comments:

   Z-score scale used in the pathway bubble plot (Figure 2C) could benefit from alternative color choices. Current gradient is a bit muddy and clarity for the reader could be improved by more distinct color options, particularly in the transition from positive to negative Z-score.

   Authors’ response. As suggested, we modified the z-score-representing colors using a more distinct gradient especially in the positive to negative transition in Figure 2B.

   Clarification on the rationale for selecting the "top 18" pathways would be helpful, as it is not clear if this cutoff was chosen arbitrarily or reflects a specific statistical or biological threshold.

   Authors’ response. As now better explained (see comment regarding Major point: Transcriptomics), we used a cut-off of -log(p-value) above or equal to 9 for pathways enriched in DEGs of the D0 vs D3 comparison for both WT and Trim32 KO. The threshold is now included in the Results section and the pathways (shared between WT and Trim32 KO and unique) are listed as Fig. EV3C.

   The authors alternates between using "Trim 32 KO clones" and "KO clones" throughout the manuscript. Consistent terminology across figures and text would improve readability.

   Authors’ response. We thank the Reviewer for this remark, and we apologise for having overlooked it. We amended this throughout the manuscript by always using for clarity “Trim32 KO clones/cells”.

   Cell culture methodology does not specify passage number or culture duration (only "At confluence") before differentiation. This is important, as C2C12 differentiation potential can drift with extended passaging.

   Authors’ response. We agree with the Reviewer that C2C12 passaging can reduce the differentiation potential of this myoblast cell lines; this is indeed the main reason why we decided to employ WT clones, which underwent the same editing process as those that resulted mutated in the Trim32 gene, as reference controls throughout our study. We apologise for not indicating the passages in the first version of the manuscript that now is amended as per here below in the Methods section:

   “The C2C12 parental cells used in this study were maintained within passages 3–8. All clonal cell lines (see below) were utilized within 10 passages following gene editing. In all experiments, WT and Trim32 KO clones of comparable passage numbers were used to ensure consistency and minimize passage-related variability.”

   Reviewer #2 (Significance (Required)):

   General Assessment:

   *This study provides a thorough investigation of Trim32's role the processes related to skeletal muscle differentiation using a CRISPR-Cas9 knockout C2C12 model. The strengths of this study lie in the multi-layered experimental approach as the authors incorporated transcriptomics, cell cycle profiling, and stability assays which collectively build a strong case for their hypothesis that Trim32 is a key factor in the normal regulation of myogenesis. The work is also strengthened by the use of multiple biological and technical replicates, particularly the independent KO clones which helps address potential clonal variation issues that could occur. The largest limitation to this study is that, while the c-Myc mechanism is well explored, the other Trim32-dependent pathways associated with the disruption (implicated by the incomplete rescue by c-Myc knockdown) are not as well addressed. Overall however, the study convincingly identifies a critical function for Trim32 during skeletal muscle differentiation. *

   • Advance: *
   • To my knowledge, this is the first study to demonstrate the mRNA stability level of c-Myc regulation by Trim32, rather than through the ubiquitin-mediated protein degradation. This work will advance the current understanding and provide a more complete understanding of Trim32's role in c-Myc regulation. Beyond c-Myc, this work highlights the idea that TRIM family proteins can influence RNA stability which could implicate a broader role in RNA biology and has potential for future therapeutic targeting. *
   • Audience: *
   • This research will be of interest to an audience that focuses on broad skeletal muscle biology but primarily to readers with more focused research such as myogenesis and neuromuscular disease (LGMDR8 in particular) where the defined Trim32 governance over early differentiation checkpoints will be of interest. It will also provide mechanistic insights to those outside of skeletal muscle that study TRIM family proteins, ubiquitin biology, and RNA regulation. For translational/clinical researchers, it identifies the Trim32/c-Myc axis as a potential therapeutic target for LGMDR8 and related muscular dystrophies.*

   *Expertise: *

   • My expertise lies in skeletal muscle biology, gene editing, transgenic mouse models, and bioinformatics. I feel confident evaluating the data and conclusions as presented.*

   Reviewer #3 (Evidence, reproducibility and clarity (Required)):

   • In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. Translation inhibition experiments suggest that TRIM32 promotes c-Myc mRNA destabilization, but this conclusion is insufficiently substantiated. The authors also perform rescue experiments, showing that c-Myc knockdown in Trim32-deficient cells alleviates some differentiation defects. However, this rescue is not quantified, was conducted in only two of the three knockout lines, and is supported by inappropriate statistical analysis of gene expression. Overall, the manuscript in its current form has substantial weaknesses that preclude publication. Beyond statistical issues, the major concerns are: (1) exclusive reliance on the immortalized C2C12 line, with no validation in primary/satellite cells or in vivo, (2) insufficient mechanistic evidence that TRIM32 acts directly on c-Myc mRNA, and (3) overinterpretation of disease relevance in the absence of supporting patient or in vivo data. Please find more details below:*

   We thank the Reviewer for the in-depth assessment of our work and precious suggestions to improve the manuscript. We have carefully addressed some of the concerns raised, as detailed here, while others, which require more experimental efforts, will be addressed as detailed in the Revision Plan.

   - TRIM32 complementation / rescue experiments to exclude clonal or off-target CRISPR effects and show specificity are lacking.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   - The authors link their in vitro findings to LGMDR8 pathogenesis and propose that the Trim32-c-Myc axis may serve as a central regulator of muscle regeneration in the disease. However, LGMDR8 is a complex disorder, and connecting muscle wasting in patients to differentiation assays in C2C12 cells is difficult to justify. No direct evidence is provided that the proposed mRNA mechanism operates in patient-derived samples or in mouse satellite cells. Moreover, the partial rescue achieved by c-Myc knockdown (which does not fully restore myotube morphology or differentiation index) further suggests that the disease connection is not straightforward. Validation of the TRIM32-c-Myc axis in a physiologically relevant system, such as LGMD patient myoblasts or Trim32 mutant mouse cells, would greatly strengthen the claim.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   -Some gene expression changes from the RNA-seq study in Figure 2 should be validated by qPCR

   Authors’ response. We thank the reviewer for this suggestion. This point will be addressed as detailed in the Revision Plan. We have selected several transcripts that will be evaluated in independent samples in order to validate the RNAseq results.

   - The paper shows siRNA knockdown of c-Myc in KO restores Myogenin RNA/protein but does not fully rescue myotube morphology or differentiation index. This suggests that Trim32 controls additional effectors beyond c-Myc; yet the authors do not pursue other candidate mediators identified in the RNA-seq. The manuscript would be strengthened by systematically testing whether other deregulated transcripts contribute to the phenotype.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   - There are concerns with experimental/statistical issues and insufficient replicate reporting. The authors use unpaired two-tailed Student's t-test across many comparisons; multiple testing corrections or ANOVA where appropriate should be used. In Figure EV5B and Figure 6B, the authors perform statistical analyses with control values set to 1. This method masks the inherent variability between experiments and artificially augments p values. Control sample values need to be normalized to one another to have reliable statistical analysis. Myotube morphology and differentiation index quantifications need clear description of fields counted, blind analysis, and number of biological replicates.

   Authors’ response. We thank the Reviewer for raising this point.

   Regarding the replicates, we clarified in the Methods and Legends that the Trim32 KO experiments have been performed on 3 biological replicates (independent clones) and the same for the reference control (3 independent WT clones), except for the Fig. 6 experiments that were performed on 2 Trim32 KO and 2 WT clones. All the Western Blots, immunofluorescence, qPCR data are representative of the results of at least 3 independent experiments unless otherwise stated. We reported the number and type of replicates as well as the microscope fields analyzed.

   We repeated the statistical analyses of the data in Figure 5G, EV5D, EV5E, employing more appropriately the 2-way-ANOVA test, as suggested, and we now reported this info in the graphs and legends.

   We thank the Reviewer for raising this point, we agree and substituted the graphs in Fig. EV5B and 6B showing the control values normalised as suggested. The statistical analyses now reflect this change.

   -Some English mistakes require additional read-throughs. For example: "Indeed, Trim32 has no effect on the stability of c-Myc mRNA in proliferating conditions, but upon induction of differentiation the stability of c-Myc mRNA resulted enhanced in Trim32 KO clones (Fig. 5G, Fig. EV5D and 5E)."

   Authors’ response. We re-edited this revised version of the manuscript as suggested.

   -Results in Figure 5A should be quantified

   Authors’ response. We amended this point by quantifying the results shown in Fig. 5A, we added the graph of the quantification of 3 experimental replicates to the Figure. Quantification confirms that no statistically significant difference is observed. The Figure and the relative legend are modified accordingly.

   -Based on the nuclear marker p84, the separation of cytoplasmic and nuclear fractions is not ideal in Figure 5D

   Authors’ response. We agree with the Reviewer that the presence of p84 also in the cytoplasmic fraction is not ideal. Regrettably, we observed this faint p84 band in all the experiments performed. We think however, that this is not impacting on the result that clearly shows that c-Myc and Trim32 are never detected in the same compartment.

   -In Figure 6, it is not appropriate to perform statistical analyses on only two data points per condition.

   Authors’ response. We agree with the Reviewer and we now show the graph of the results of the 3 technical replicates for 2 biological replicates and do not indicate any statistics (Fig. 6B). The graph was also modified according to a previous point raised.

   -The nuclear MYOG phenotype is very interesting; could this be related to requirements of TRIM32 in fusion?

   Authors’ response. We agree with the Reviewer that Trim32 might also be necessary for myoblast fusion. This point is however beyond the scope of the present study and will be addressed in future work.

   - The hypothesis that TRIM32 destabilizes c-Myc mRNA is intriguing but requires stronger mechanistic support. This would be more convincing with RNA immunoprecipitation to test direct association with c-Myc mRNA, and/or co-immunoprecipitation to identify interactions between TRIM32 and proteins involved in mRNA stability. The study would also be strengthened by reporter assays, such as c-Myc 3′UTR luciferase constructs in WT and KO cells, to directly demonstrate 3′UTR-dependent regulation of mRNA stability.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   Reviewer #3 (Significance (Required)):

   The manuscript presents a minor conceptual advance in understanding TRIM32 function in myogenic differentiation. Its main limitation is that all experiments were performed in C2C12 cells. While C2C12 are a classical system to study muscle differentiation, they are an immortalized, long-cultured, and genetically unstable line that represents a committed myoblast stage rather than bona fide satellite cells. They therefore do not fully model the biology of early regenerative responses. Several TRIM32 phenotypes reported in the literature differ between primary satellite cells and cell lines, and the authors themselves note such discrepancies. Extrapolating these findings to LGMDR8 pathogenesis without validation in primary human myoblasts, satellite cell assays, or in vivo regeneration models is therefore not justified. Previous work has already established clear roles for TRIM32 in mouse satellite cells in vivo and in patient myoblasts in vitro, whereas this study introduces a novel link to c-Myc regulation during differentiation. In addition, without mechanistic evidence, the central claim that TRIM32 regulates c-Myc mRNA stability remains descriptive and incomplete. Nevertheless, the results will be of interest to researchers studying LGMD and to those exploring TRIM32 biology in broader contexts. I review this manuscript as a muscle biologist with expertise in satellite cell biology and transcriptional regulation.

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Reply to the Reviewers

   I thank the Referees for their...

   Referee #1

   1. The authors should provide more information when...

   Responses

   • The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A).
   • Though this is not stated in the MS

   1. Figure 6: Why has only...

   Response: We expanded the comparison

   Minor comments:

   1. The text contains several...

   Response: We added...

   Referee #2

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Reply to the Reviewers

   I thank the Referees for their...

   Referee #1

   1. The authors should provide more information when...

   Responses

   • The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A).
   • Though this is not stated in the MS

   1. Figure 6: Why has only...

   Response: We expanded the comparison

   Minor comments:

   1. The text contains several...

   Response: We added...

   Referee #2

   Read the original source
2. 

   Review Commons

   Dec 11, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #3

   Evidence, reproducibility and clarity

   In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. …

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #3

   Evidence, reproducibility and clarity

   In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. Translation inhibition experiments suggest that TRIM32 promotes c-Myc mRNA destabilization, but this conclusion is insufficiently substantiated. The authors also perform rescue experiments, showing that c-Myc knockdown in Trim32-deficient cells alleviates some differentiation defects. However, this rescue is not quantified, was conducted in only two of the three knockout lines, and is supported by inappropriate statistical analysis of gene expression. Overall, the manuscript in its current form has substantial weaknesses that preclude publication. Beyond statistical issues, the major concerns are: (1) exclusive reliance on the immortalized C2C12 line, with no validation in primary/satellite cells or in vivo, (2) insufficient mechanistic evidence that TRIM32 acts directly on c-Myc mRNA, and (3) overinterpretation of disease relevance in the absence of supporting patient or in vivo data. Please find more details below:

   • TRIM32 complementation / rescue experiments to exclude clonal or off-target CRISPR effects and show specificity are lacking.
   • The authors link their in vitro findings to LGMDR8 pathogenesis and propose that the Trim32-c-Myc axis may serve as a central regulator of muscle regeneration in the disease. However, LGMDR8 is a complex disorder, and connecting muscle wasting in patients to differentiation assays in C2C12 cells is difficult to justify. No direct evidence is provided that the proposed mRNA mechanism operates in patient-derived samples or in mouse satellite cells. Moreover, the partial rescue achieved by c-Myc knockdown (which does not fully restore myotube morphology or differentiation index) further suggests that the disease connection is not straightforward. Validation of the TRIM32-c-Myc axis in a physiologically relevant system, such as LGMD patient myoblasts or Trim32 mutant mouse cells, would greatly strengthen the claim. -Some gene expression changes from the RNA-seq study in Figure 2 should be validated by qPCR
   • The paper shows siRNA knockdown of c-Myc in KO restores Myogenin RNA/protein but does not fully rescue myotube morphology or differentiation index. This suggests that Trim32 controls additional effectors beyond c-Myc; yet the authors do not pursue other candidate mediators identified in the RNA-seq. The manuscript would be strengthened by systematically testing whether other deregulated transcripts contribute to the phenotype.
   • There are concerns with experimental/statistical issues and insufficient replicate reporting. The authors use unpaired two-tailed Student's t-test across many comparisons; multiple testing corrections or ANOVA where appropriate should be used. In Figure EV5B and Figure 6B, the authors perform statistical analyses with control values set to 1. This method masks the inherent variability between experiments and artificially augments p values. Control sample values need to be normalized to one another to have reliable statistical analysis. Myotube morphology and differentiation index quantifications need clear description of fields counted, blind analysis, and number of biological replicates. -Some English mistakes require additional read-throughs. For example: "Indeed, Trim32 has no effect on the stability of c-Myc mRNA in proliferating conditions, but upon induction of differentiation the stability of c-Myc mRNA resulted enhanced in Trim32 KO clones (Fig. 5G, Fig. EV5D and 5E)." -Results in Figure 5A should be quantified -Based on the nuclear marker p84, the separation of cytoplasmic and nuclear fractions is not ideal in Figure 5D -In Figure 6, it is not appropriate to perform statistical analyses on only two data points per condition. -The nuclear MYOG phenotype is very interesting; could this be related to requirements of TRIM32 in fusion?
   • The hypothesis that TRIM32 destabilizes c-Myc mRNA is intriguing but requires stronger mechanistic support. This would be more convincing with RNA immunoprecipitation to test direct association with c-Myc mRNA, and/or co-immunoprecipitation to identify interactions between TRIM32 and proteins involved in mRNA stability. The study would also be strengthened by reporter assays, such as c-Myc 3′UTR luciferase constructs in WT and KO cells, to directly demonstrate 3′UTR-dependent regulation of mRNA stability.

   Significance

   The manuscript presents a minor conceptual advance in understanding TRIM32 function in myogenic differentiation. Its main limitation is that all experiments were performed in C2C12 cells. While C2C12 are a classical system to study muscle differentiation, they are an immortalized, long-cultured, and genetically unstable line that represents a committed myoblast stage rather than bona fide satellite cells. They therefore do not fully model the biology of early regenerative responses. Several TRIM32 phenotypes reported in the literature differ between primary satellite cells and cell lines, and the authors themselves note such discrepancies. Extrapolating these findings to LGMDR8 pathogenesis without validation in primary human myoblasts, satellite cell assays, or in vivo regeneration models is therefore not justified. Previous work has already established clear roles for TRIM32 in mouse satellite cells in vivo and in patient myoblasts in vitro, whereas this study introduces a novel link to c-Myc regulation during differentiation. In addition, without mechanistic evidence, the central claim that TRIM32 regulates c-Myc mRNA stability remains descriptive and incomplete. Nevertheless, the results will be of interest to researchers studying LGMD and to those exploring TRIM32 biology in broader contexts. I review this manuscript as a muscle biologist with expertise in satellite cell biology and transcriptional regulation.

   Read the original source
3. 

   Review Commons

   Dec 11, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #2

   Evidence, reproducibility and clarity

   Summary:

   In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic …

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #2

   Evidence, reproducibility and clarity

   Summary:

   In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic signaling in the Trim32 KO cells, leading to a disruption of myotube formation in-vitro. Interestingly, while previous studies have focused on Trim32's role in protein ubiquitination and degradation of c-Myc, the authors provide evidence that Trim32-regulation of c-Myc occurs at the level of mRNA stability. The authors show that the sustained c-Myc expression in Trim32 knockout cells disrupts the timely expression of key myogenic factors and interferes with critical withdrawal of myoblasts from the cell cycle required for myotube formation. Overall, the study offers a new insight into how Trim32 regulates early myogenic progression and highlights a potential therapeutic target for addressing the defects in muscular regeneration observed in LGMDR8.

   Major Comments:

   The work is a bit incremental based on this: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030445 And this: https://www.nature.com/articles/s41418-018-0129-0 To their credit, the authors do cite the above papers.

   The authors do provide compelling evidence that Trim32 deficiency disrupts C2C12 myogenic differentiation and sustained c-Myc expression contributes to this defective process. However, while knockdown of c-Myc does restore Myogenin levels, it was not sufficient to normalize myotube morphology or differentiation index, suggesting an incomplete picture of the Trim32-dependent pathways involved. The authors should qualify their claim by emphasizing that c-Myc regulation is a major, but not exclusive, mechanism underlying the observed defects. This will prevent an overgeneralization and better align the conclusions with the author's data. The authors provide a thorough and well-executed interrogation of cell cycle dynamics in Trim32 KO clones, combining phosphor-histone H3 flow cytometry of DNA content, and CFSE proliferation assays. These complementary approaches convincingly show that, while proliferation states remain similar in WT and KO cells, Trim32-deficient myoblasts fail in their normal withdraw from the cell cycle during exposure to differentiation-inducing conditions. This work adds clarity to a previously inconsistent literature and greatly strengthens the study.

   The transcriptomic analysis (detailed In the "Transcriptomic analysis of Trim32 WT and KO clones along early differentiation" section of Results) is central to the manuscript and provides strong evidence that Trim32 deficiency disrupts normal differentiation processes. However, the description of the pathway enrichment results is highly detailed and somewhat compressed, which may make it challenging for readers to following the key biological 'take-homes'. The narrative quickly moves across their multiple analyses like MDS, clustering, heatmaps, and bubble plots without pausing to guide the reader through what each analysis contributes to the overall biological interpretation. As a result, the key findings (reduced muscle development pathways in KO cells and enrichment of cell cycle-related pathways) can feel somewhat muted. The authors may consider reorganizing this section, so the primary biological insights are highlighted and supported by each of their analyses. This would allow the biological implications to be more accessible to a broader readership.

   The work would be greatly strengthened by the conclusion of LGMDR8 primary cells, and rescue experiments of TRIM32 to explore myogenesis. Also, EU (5-ethynyl uridine) pulse-chase experiments to label nascent and stable RNA coupled with MYC pulldowns and qPCR (or RNA-sequencing of both pools) would further enhance the claim that MYC stability is being affected.

   "On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025)." Also address and discuss the following, as what is currently written is not entirely accurate: https://www.embopress.org/doi/full/10.1038/s44319-024-00299-z and https://journals.physiology.org/doi/prev/20250724-aop/abs/10.1152/ajpcell.00528.2025

   Minor Comments:

   Z-score scale used in the pathway bubble plot (Figure 2C) could benefit from alternative color choices. Current gradient is a bit muddy and clarity for the reader could be improved by more distinct color options, particularly in the transition from positive to negative Z-score.

   Clarification on the rationale for selecting the "top 18" pathways would be helpful, as it is not clear if this cutoff was chosen arbitrarily or reflects a specific statistical or biological threshold.

   The authors alternates between using "Trim 32 KO clones" and "KO clones" throughout the manuscript. Consistent terminology across figures and text would improve readability.

   Cell culture methodology does not specify passage number or culture duration (only "At confluence") before differentiation. This is important, as C2C12 differentiation potential can drift with extended passaging.

   Significance

   General Assessment:

   This study provides a thorough investigation of Trim32's role the processes related to skeletal muscle differentiation using a CRISPR-Cas9 knockout C2C12 model. The strengths of this study lie in the multi-layered experimental approach as the authors incorporated transcriptomics, cell cycle profiling, and stability assays which collectively build a strong case for their hypothesis that Trim32 is a key factor in the normal regulation of myogenesis. The work is also strengthened by the use of multiple biological and technical replicates, particularly the independent KO clones which helps address potential clonal variation issues that could occur. The largest limitation to this study is that, while the c-Myc mechanism is well explored, the other Trim32-dependent pathways associated with the disruption (implicated by the incomplete rescue by c-Myc knockdown) are not as well addressed. Overall however, the study convincingly identifies a critical function for Trim32 during skeletal muscle differentiation.

   Advance:

   To my knowledge, this is the first study to demonstrate the mRNA stability level of c-Myc regulation by Trim32, rather than through the ubiquitin-mediated protein degradation. This work will advance the current understanding and provide a more complete understanding of Trim32's role in c-Myc regulation. Beyond c-Myc, this work highlights the idea that TRIM family proteins can influence RNA stability which could implicate a broader role in RNA biology and has potential for future therapeutic targeting.

   Audience:

   This research will be of interest to an audience that focuses on broad skeletal muscle biology but primarily to readers with more focused research such as myogenesis and neuromuscular disease (LGMDR8 in particular) where the defined Trim32 governance over early differentiation checkpoints will be of interest. It will also provide mechanistic insights to those outside of skeletal muscle that study TRIM family proteins, ubiquitin biology, and RNA regulation. For translational/clinical researchers, it identifies the Trim32/c-Myc axis as a potential therapeutic target for LGMDR8 and related muscular dystrophies.

   Expertise:

   My expertise lies in skeletal muscle biology, gene editing, transgenic mouse models, and bioinformatics. I feel confident evaluating the data and conclusions as presented.

   Read the original source
4. 

   Review Commons

   Dec 11, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #1

   Evidence, reproducibility and clarity

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases. In my opinion, a few aspects would improve the manuscript.

   Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studi…

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #1

   Evidence, reproducibility and clarity

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases. In my opinion, a few aspects would improve the manuscript.

   Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studies investigating whether Tim32 binds directly to c-Myc RNA. Moreover, although possibly beyond the scope of this study, an unbiased screening of RNA species binding to Trim32 would be informative.
   2. If possible, studies in which the overexpression of different mutants presenting specific altered functional domains (NHL domain known to bind RNAs and Ring domain reportedly involved in protein ubiquitination) would be used to test if they are capable or incapable of rescuing the reported alteration of Trim32 KO cell lines in c-Myc expression and muscle maturation. An optional aspect that might be interesting to explore is whether the alterations in c-Myc expression observed in C2C12 might be replicated with primary myoblasts or satellite cells devoid of Trim32.

   I also have a few minor points to highlight:

   • It is unclear if the differences highlighted in graphs 5G, EV5D, and EV5E are statistically significant.
   • On page 10, it is stated that c-Myc down-regulation cannot rescue KO myotube morphology fully nor increase the differentiation index significantly, but the corresponding data is not shown. Could the authors include those quantifications in the manuscript?

   Significance

   The manuscript offers several strengths. It provides novel mechanistic insight by identifying a previously unrecognized role for Trim32 in regulating c-Myc mRNA stability during the onset of myogenic differentiation. The study is supported by a robust methodology that integrates CRISPR/Cas9 gene editing, transcriptomic profiling, flow cytometry, biochemical assays, and rescue experiments using siRNA knockdown. Furthermore, the work has a disease relevance, as it uncovers a mechanistic link between Trim32 deficiency and impaired myogenesis, with implications for the pathogenesis of LGMDR8. At the same time, the study has some limitations. The findings rely exclusively on the C2C12 myoblast cell line, which may not fully represent primary satellite cell or in vivo biology. The functional rescue achieved through c-Myc knockdown is only partial, restoring Myogenin expression but not the full differentiation index or morphology, indicating that additional mechanisms are likely involved. Although evidence supports a role for Trim32 in mRNA destabilization, the precise molecular partners-such as RNA-binding activity, microRNA involvement, or ligase function-remain undefined. Some discrepancies with previous studies, including Trim32-mediated protein degradation of c-Myc, are acknowledged but not experimentally resolved. Moreover, functional validation in animal models or patient-derived cells is currently lacking.

   Despite these limitations, the study represents an advancement for the field. It shifts the conceptual framework from Trim32's canonical role in protein ubiquitination to a novel function in RNA regulation during myogenesis. It also raises potential clinical implications by suggesting that targeting the Trim32-c-Myc axis, or modulating c-Myc stability, may represent a therapeutic strategy for LGMDR8. This work will be of particular interest to muscle biology researchers studying myogenesis and the molecular basis of muscle disease, RNA biology specialists investigating post-transcriptional regulation and mRNA stability, and neuromuscular disease researchers and clinicians seeking to identify new molecular targets for therapeutic intervention in LGMDR8.

   The Reviewer expressing this opinion is an expert in muscle stem cells, muscle regeneration, and muscle development.

   Read the original source
5. 

   Review Commons

   Nov 4, 2025

   Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Reply to the reviewers

   Reviewer #1 (Evidence, reproducibility and clarity (Required)):

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases.

   We thank the Reviewer for appreciating our work and for their valuable suggestions to improve our manuscript. We have carefully addressed some of the …

   Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Reply to the reviewers

   Reviewer #1 (Evidence, reproducibility and clarity (Required)):

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases.

   We thank the Reviewer for appreciating our work and for their valuable suggestions to improve our manuscript. We have carefully addressed some of the concerns raised, as detailed here, while others, which require more experimental efforts, will be addressed as detailed in the Revision Plan.

   In my opinion, a few aspects would improve the manuscript. Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studies investigating whether Tim32 binds directly to c-Myc RNA. Moreover, although possibly beyond the scope of this study, an unbiased screening of RNA species binding to Trim32 would be informative. Authors’ response. This point will be addressed as detailed in the Revision Plan

   If possible, studies in which the overexpression of different mutants presenting specific altered functional domains (NHL domain known to bind RNAs and Ring domain reportedly involved in protein ubiquitination) would be used to test if they are capable or incapable of rescuing the reported alteration of Trim32 KO cell lines in c-Myc expression and muscle maturation.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   An optional aspect that might be interesting to explore is whether the alterations in c-Myc expression observed in C2C12 might be replicated with primary myoblasts or satellite cells devoid of Trim32.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   I also have a few minor points to highlight:

   • • It is unclear if the differences highlighted in graphs 5G, EV5D, and EV5E are statistically significant.*

   Authors’ response. We thank the Reviewer for raising this point. We now indicated the statistical analyses performed on the data presented in the mentioned figures (according also to a point of Reviewer #3). According to the conclusion that Trim32 is necessary for proper regulation of c-Myc transcript stability, using 2-way-ANOVA, the data now reported as Figure 5G show the statistically significant effect of the genotype at 6h (right-hand graph) but not at D0 (left-hand graph). In the graphs of Fig. EV5 D and E at D0 no significant changes are observed whereas at 6h the data show significant difference at the 40 min time point. We included this info in the graphs and in the corresponding legends.

   - On page 10, it is stated that c-Myc down-regulation cannot rescue KO myotube morphology fully nor increase the differentiation index significantly, but the corresponding data is not shown. Could the authors include those quantifications in the manuscript?

   Authors’ response. As suggested, we included the graph showing the differentiation index upon c-Myc silencing in the Trim32 KO clones and in the WT clones, as a novel panel in Figure 6 (Fig. 6D). As already reported in the text, a partial recovery of differentiation index is observed but the increase is not statistically significant. In contrast, no changes are observed applying the same silencing in the WT cells. Legend and text were modified accordingly.

   Reviewer #1 (Significance (Required)):

   *The manuscript offers several strengths. It provides novel mechanistic insight by identifying a previously unrecognized role for Trim32 in regulating c-Myc mRNA stability during the onset of myogenic differentiation. The study is supported by a robust methodology that integrates CRISPR/Cas9 gene editing, transcriptomic profiling, flow cytometry, biochemical assays, and rescue experiments using siRNA knockdown. Furthermore, the work has a disease relevance, as it uncovers a mechanistic link between Trim32 deficiency and impaired myogenesis, with implications for the pathogenesis of LGMDR8. *

   • At the same time, the study has some limitations. The findings rely exclusively on the C2C12 myoblast cell line, which may not fully represent primary satellite cell or in vivo biology. The functional rescue achieved through c-Myc knockdown is only partial, restoring Myogenin expression but not the full differentiation index or morphology, indicating that additional mechanisms are likely involved. Although evidence supports a role for Trim32 in mRNA destabilization, the precise molecular partners-such as RNA-binding activity, microRNA involvement, or ligase function-remain undefined. Some discrepancies with previous studies, including Trim32-mediated protein degradation of c-Myc, are acknowledged but not experimentally resolved. Moreover, functional validation in animal models or patient-derived cells is currently lacking. Despite these limitations, the study represents an advancement for the field. It shifts the conceptual framework from Trim32's canonical role in protein ubiquitination to a novel function in RNA regulation during myogenesis. It also raises potential clinical implications by suggesting that targeting the Trim32-c-Myc axis, or modulating c-Myc stability, may represent a therapeutic strategy for LGMDR8. This work will be of particular interest to muscle biology researchers studying myogenesis and the molecular basis of muscle disease, RNA biology specialists investigating post-transcriptional regulation and mRNA stability, and neuromuscular disease researchers and clinicians seeking to identify new molecular targets for therapeutic intervention in LGMDR8. *
   • The Reviewer expressing this opinion is an expert in muscle stem cells, muscle regeneration, and muscle development.*

   Reviewer #2 (Evidence, reproducibility and clarity (Required)):

   *Summary: *

   • In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic signaling in the Trim32 KO cells, leading to a disruption of myotube formation in-vitro. Interestingly, while previous studies have focused on Trim32's role in protein ubiquitination and degradation of c-Myc, the authors provide evidence that Trim32-regulation of c-Myc occurs at the level of mRNA stability. The authors show that the sustained c-Myc expression in Trim32 knockout cells disrupts the timely expression of key myogenic factors and interferes with critical withdrawal of myoblasts from the cell cycle required for myotube formation. Overall, the study offers a new insight into how Trim32 regulates early myogenic progression and highlights a potential therapeutic target for addressing the defects in muscular regeneration observed in LGMDR8.*

   We thank the Reviewer for valuing our work and for their appreciated suggestions to improve our manuscript. We have carefully addressed some of the concerns raised as detailed here, while others, which require more laborious experimental efforts, will be addressed as reported in the Revision Plan.

   Major Comments:

   The work is a bit incremental based on this:

   *https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030445 *

   • And this:*

   *https://www.nature.com/articles/s41418-018-0129-0 *

   • To their credit, the authors do cite the above papers.*

   Authors’ response. We thank the Reviewer for this careful evaluation of our work against the current literature and for recognising the contribution of our findings to the understanding of myogenesis complex picture in which the involvement of Trim32 and c-Myc, and of the Trim32-c-Myc axis, can occur at several stages and likely in narrow time windows along the process, thus possibly explaining some reports inconsistencies.

   The authors do provide compelling evidence that Trim32 deficiency disrupts C2C12 myogenic differentiation and sustained c-Myc expression contributes to this defective process. However, while knockdown of c-Myc does restore Myogenin levels, it was not sufficient to normalize myotube morphology or differentiation index, suggesting an incomplete picture of the Trim32-dependent pathways involved. The authors should qualify their claim by emphasizing that c-Myc regulation is a major, but not exclusive, mechanism underlying the observed defects. This will prevent an overgeneralization and better align the conclusions with the author's data.

   Authors’ response. We agree with the Reviewer and we modified our phrasing that implied Trim32-c-Myc axis as the exclusive mechanism by explicitly indicated that other pathways contribute to guarantee proper myogenesis, in the Abstract and in Discussion.

   The Abstract now reads: “… suggesting that the Trim32–c-Myc axis may represent an essential hub, although likely not the exclusive molecular mechanism, in muscle regeneration within LGMDR8 pathogenesis.”

   The Discussion now reads: “Functionally, we demonstrated that c-Myc contributes to the impaired myogenesis observed in Trim32 KO clones, although this is clearly not the only factor involved in the Trim32-mediated myogenic network; realistically other molecular mechanisms can participate in this process as also suggested by our transcriptomic results.”

   The authors provide a thorough and well-executed interrogation of cell cycle dynamics in Trim32 KO clones, combining phosphor-histone H3 flow cytometry of DNA content, and CFSE proliferation assays. These complementary approaches convincingly show that, while proliferation states remain similar in WT and KO cells, Trim32-deficient myoblasts fail in their normal withdraw from the cell cycle during exposure to differentiation-inducing conditions. This work adds clarity to a previously inconsistent literature and greatly strengthens the study.

   Authors’ response. We thank the Reviewer for appreciating our thorough analyses on cell cycle dynamics in proliferation conditions and at the onset of the differentiation process.

   The transcriptomic analysis (detailed In the "Transcriptomic analysis of Trim32 WT and KO clones along early differentiation" section of Results) is central to the manuscript and provides strong evidence that Trim32 deficiency disrupts normal differentiation processes. However, the description of the pathway enrichment results is highly detailed and somewhat compressed, which may make it challenging for readers to following the key biological 'take-homes'. The narrative quickly moves across their multiple analyses like MDS, clustering, heatmaps, and bubble plots without pausing to guide the reader through what each analysis contributes to the overall biological interpretation. As a result, the key findings (reduced muscle development pathways in KO cells and enrichment of cell cycle-related pathways) can feel somewhat muted. The authors may consider reorganizing this section, so the primary biological insights are highlighted and supported by each of their analyses. This would allow the biological implications to be more accessible to a broader readership.

   Authors’ response. We thank the Reviewer for raising this point and apologise for being too brief in describing the data, leaving indeed some points excessively implicit. As suggested, we now reorganised this session and added the lists of enriched canonical pathways relative to WT vs KO comparisons at D0 and D3 (Fig. EV3B) as well as those relative to the comparison between D0 and D3 for both WT and Trim32 KO samples (Fig. EV3C), with their relative scores. We changed the Results section “Transcriptomic analysis of Trim32 WT and Trim32 KO clones along early differentiation*” *as reported here below and modified the legends accordingly.

   The paragraph now reads: “Based on our initial observations, the absence of Trim32 already exerts a significant impact by day 3 (D3) of C2C12 myogenic differentiation. To investigate how Trim32 influences early global transcriptional changes during the proliferative phase (D0) and early differentiation (D3), we performed an unbiased transcriptomic profiling of WT and Trim32 KO clones (Fig. 2A). Multidimensional Scaling (MDS) analysis revealed clear segregation of gene expression profiles based on both time of differentiation (Dim1, 44% variance) and Trim32 genotype (Dim2, 16% variance) (Fig. 2A). Likewise, hierarchical clustering grouped WT and Trim32 KO clones into distinct clusters at both timepoints, indicating consistent genotype-specific transcriptional differences (Fig. EV3A). Differentially Expressed Genes (DEGs) were detected in the Trim32 KO transcriptome relative to WT, at both D0 and D3. In proliferating conditions, 72 genes were upregulated and 189 were downregulated whereas at D3 of differentiation, 72 genes were upregulated and 212 were downregulated. Ingenuity Pathway Analysis of the DEGs revealed the top 10 Canonical Pathways displayed in Fig. EV3B as enriched at either D0 or D3 (Fig. EV3B). Several of these pathways can underscore relevant Trim32-mediated functions though most of them represent generic functions not immediately attributable to the observed myogenesis defects.

   Notably, the transcriptional divergence between WT and Trim32 KO cells is more pronounced at D3, as evidenced by a greater separation along the MSD Dim2 axis, suggesting that Trim32-dependent transcriptional regulation intensifies during early differentiation (Fig. 2A). Given our interest in the differentiation process, we therefore focused our analyses comparing the changes occurring from D0 to D3 in WT (WT D3 vs. D0) and in Trim32 KO (KO D3 vs. D0) RNAseq data.

   Pathway enrichment analysis of D3 vs. D0 DEGs allowed the selection of the top-scored pathways for both WT and Trim32 KO data. We obtained 18 top-scored pathways enriched in each genotype (-log(p-value) ³ 9 cut-off): 14 are shared while 4 are top-ranked only in WT and 4 only in Trim32 KO (Fig. EV3C). For the following analyses, we employed thus a total of 22 distinct pathways and to better mine those relevant in the passage from the proliferation stage to the early differentiation one and that are affected by the lack of Trim32, we built a bubble plot comparing side-by-side the scores and enrichment of the 22 selected top-scored pathways above in WT and Trim32 KO (Fig. 2B). A heatmap of DEGs included within these selected pathways confirms the clustering of the samples considering both the genotypes and the timepoints highlighting gene expression differences (Fig. 2C). These pathways are mainly related to muscle development, cell cycle regulation, genome stability maintenance and few other metabolic cascades.

   As expected given the results related to Figure 1, moving from D0 to D3 WT clones showed robust upregulation of key transcripts associated with the Inactive Sarcomere Protein Complex, a category encompassing most genes in the “Striated Muscle Contraction” pathway, while in Trim32 KO clones this pathway was not among those enriched in the transition from D0 to D3 (Fig. EV3C). Detailed analyses of transcripts enclosed within this pathway revealed that on the transition from proliferation to differentiation, WT clones show upregulation of several Myosin Heavy Chain isoforms (e.g., MYH3, MYH6, MYH8), α-Actin 1 (ACTA1), α-Actinin 2 (ACTN2), Desmin (DES), Tropomodulin 1 (TMOD1), and Titin (TTN), a pattern consistent with previous reports, while these same transcripts were either non-detected or only modestly upregulated in Trim32 KO clones at D3 (Fig. 2D). This genotype-specific disparity was further confirmed by gene set enrichment barcode plots, which demonstrated significant enrichment of these muscle-related transcripts in WT cells (FDR_UP = 0.0062), but not in Trim32 KO cells (FDR_UP = 0.24) (Fig. EV3D). These findings support an early transcriptional basis for the impaired myogenesis previously observed in Trim32 KO cells.

   In addition to differences in muscle-specific gene expression, we observed that also several pathways related to cell proliferation and cell cycle regulation were more enriched in Trim32 KO cells compared to WT. This suggests that altered cell proliferation may contribute to the distinct differentiation behavior observed in Trim32 KO versus WT (Fig. 2B). Given that cell cycle exit is a critical prerequisite for the onset of myogenic differentiation and considering that previous studies on Trim32 role in cell cycle regulation have reported inconsistent findings, we further examined cell cycle dynamics under our experimental conditions to clarify Trim32 contribution to this process”

   The work would be greatly strengthened by the conclusion of LGMDR8 primary cells, and rescue experiments of TRIM32 to explore myogenesis.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   Also, EU (5-ethynyl uridine) pulse-chase experiments to label nascent and stable RNA coupled with MYC pulldowns and qPCR (or RNA-sequencing of both pools) would further enhance the claim that MYC stability is being affected.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   "On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025)." Also address and discuss the following, as what is currently written is not entirely accurate: https://www.embopress.org/doi/full/10.1038/s44319-024-00299-z and https://journals.physiology.org/doi/prev/20250724-aop/abs/10.1152/ajpcell.00528.2025

   Authors’ response. We thank the Reviewer for bringing to our attention these two publications, that indeed, add important piece of data to recapitulate the in vivo complexity of c-Myc role in myogenesis. We included this point in our Discussion.

   The Discussion now reads: “On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025). Other reports, instead, demonstrated the implication of c-Myc periodic pulses, mimicking resistance-exercise, in muscle growth, a role that cannot though be observed in our experimental model (Edman et al., 2024; Jones et al., 2025).”

   Minor Comments:

   Z-score scale used in the pathway bubble plot (Figure 2C) could benefit from alternative color choices. Current gradient is a bit muddy and clarity for the reader could be improved by more distinct color options, particularly in the transition from positive to negative Z-score.

   Authors’ response. As suggested, we modified the z-score-representing colors using a more distinct gradient especially in the positive to negative transition in Figure 2B.

   Clarification on the rationale for selecting the "top 18" pathways would be helpful, as it is not clear if this cutoff was chosen arbitrarily or reflects a specific statistical or biological threshold.

   Authors’ response. As now better explained (see comment regarding Major point: Transcriptomics), we used a cut-off of -log(p-value) above or equal to 9 for pathways enriched in DEGs of the D0 vs D3 comparison for both WT and Trim32 KO. The threshold is now included in the Results section and the pathways (shared between WT and Trim32 KO and unique) are listed as Fig. EV3C.

   The authors alternates between using "Trim 32 KO clones" and "KO clones" throughout the manuscript. Consistent terminology across figures and text would improve readability.

   Authors’ response. We thank the Reviewer for this remark, and we apologise for having overlooked it. We amended this throughout the manuscript by always using for clarity “Trim32 KO clones/cells”.

   Cell culture methodology does not specify passage number or culture duration (only "At confluence") before differentiation. This is important, as C2C12 differentiation potential can drift with extended passaging.

   Authors’ response. We agree with the Reviewer that C2C12 passaging can reduce the differentiation potential of this myoblast cell lines; this is indeed the main reason why we decided to employ WT clones, which underwent the same editing process as those that resulted mutated in the Trim32 gene, as reference controls throughout our study. We apologise for not indicating the passages in the first version of the manuscript that now is amended as per here below in the Methods section:

   “The C2C12 parental cells used in this study were maintained within passages 3–8. All clonal cell lines (see below) were utilized within 10 passages following gene editing. In all experiments, WT and Trim32 KO clones of comparable passage numbers were used to ensure consistency and minimize passage-related variability.”

   Reviewer #2 (Significance (Required)):

   General Assessment:

   *This study provides a thorough investigation of Trim32's role the processes related to skeletal muscle differentiation using a CRISPR-Cas9 knockout C2C12 model. The strengths of this study lie in the multi-layered experimental approach as the authors incorporated transcriptomics, cell cycle profiling, and stability assays which collectively build a strong case for their hypothesis that Trim32 is a key factor in the normal regulation of myogenesis. The work is also strengthened by the use of multiple biological and technical replicates, particularly the independent KO clones which helps address potential clonal variation issues that could occur. The largest limitation to this study is that, while the c-Myc mechanism is well explored, the other Trim32-dependent pathways associated with the disruption (implicated by the incomplete rescue by c-Myc knockdown) are not as well addressed. Overall however, the study convincingly identifies a critical function for Trim32 during skeletal muscle differentiation. *

   • Advance: *
   • To my knowledge, this is the first study to demonstrate the mRNA stability level of c-Myc regulation by Trim32, rather than through the ubiquitin-mediated protein degradation. This work will advance the current understanding and provide a more complete understanding of Trim32's role in c-Myc regulation. Beyond c-Myc, this work highlights the idea that TRIM family proteins can influence RNA stability which could implicate a broader role in RNA biology and has potential for future therapeutic targeting. *
   • Audience: *
   • This research will be of interest to an audience that focuses on broad skeletal muscle biology but primarily to readers with more focused research such as myogenesis and neuromuscular disease (LGMDR8 in particular) where the defined Trim32 governance over early differentiation checkpoints will be of interest. It will also provide mechanistic insights to those outside of skeletal muscle that study TRIM family proteins, ubiquitin biology, and RNA regulation. For translational/clinical researchers, it identifies the Trim32/c-Myc axis as a potential therapeutic target for LGMDR8 and related muscular dystrophies.*

   *Expertise: *

   • My expertise lies in skeletal muscle biology, gene editing, transgenic mouse models, and bioinformatics. I feel confident evaluating the data and conclusions as presented.*

   Reviewer #3 (Evidence, reproducibility and clarity (Required)):

   • In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. Translation inhibition experiments suggest that TRIM32 promotes c-Myc mRNA destabilization, but this conclusion is insufficiently substantiated. The authors also perform rescue experiments, showing that c-Myc knockdown in Trim32-deficient cells alleviates some differentiation defects. However, this rescue is not quantified, was conducted in only two of the three knockout lines, and is supported by inappropriate statistical analysis of gene expression. Overall, the manuscript in its current form has substantial weaknesses that preclude publication. Beyond statistical issues, the major concerns are: (1) exclusive reliance on the immortalized C2C12 line, with no validation in primary/satellite cells or in vivo, (2) insufficient mechanistic evidence that TRIM32 acts directly on c-Myc mRNA, and (3) overinterpretation of disease relevance in the absence of supporting patient or in vivo data. Please find more details below:*

   We thank the Reviewer for the in-depth assessment of our work and precious suggestions to improve the manuscript. We have carefully addressed some of the concerns raised, as detailed here, while others, which require more experimental efforts, will be addressed as detailed in the Revision Plan.

   - TRIM32 complementation / rescue experiments to exclude clonal or off-target CRISPR effects and show specificity are lacking.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   - The authors link their in vitro findings to LGMDR8 pathogenesis and propose that the Trim32-c-Myc axis may serve as a central regulator of muscle regeneration in the disease. However, LGMDR8 is a complex disorder, and connecting muscle wasting in patients to differentiation assays in C2C12 cells is difficult to justify. No direct evidence is provided that the proposed mRNA mechanism operates in patient-derived samples or in mouse satellite cells. Moreover, the partial rescue achieved by c-Myc knockdown (which does not fully restore myotube morphology or differentiation index) further suggests that the disease connection is not straightforward. Validation of the TRIM32-c-Myc axis in a physiologically relevant system, such as LGMD patient myoblasts or Trim32 mutant mouse cells, would greatly strengthen the claim.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   -Some gene expression changes from the RNA-seq study in Figure 2 should be validated by qPCR

   Authors’ response. We thank the reviewer for this suggestion. This point will be addressed as detailed in the Revision Plan. We have selected several transcripts that will be evaluated in independent samples in order to validate the RNAseq results.

   - The paper shows siRNA knockdown of c-Myc in KO restores Myogenin RNA/protein but does not fully rescue myotube morphology or differentiation index. This suggests that Trim32 controls additional effectors beyond c-Myc; yet the authors do not pursue other candidate mediators identified in the RNA-seq. The manuscript would be strengthened by systematically testing whether other deregulated transcripts contribute to the phenotype.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   - There are concerns with experimental/statistical issues and insufficient replicate reporting. The authors use unpaired two-tailed Student's t-test across many comparisons; multiple testing corrections or ANOVA where appropriate should be used. In Figure EV5B and Figure 6B, the authors perform statistical analyses with control values set to 1. This method masks the inherent variability between experiments and artificially augments p values. Control sample values need to be normalized to one another to have reliable statistical analysis. Myotube morphology and differentiation index quantifications need clear description of fields counted, blind analysis, and number of biological replicates.

   Authors’ response. We thank the Reviewer for raising this point.

   Regarding the replicates, we clarified in the Methods and Legends that the Trim32 KO experiments have been performed on 3 biological replicates (independent clones) and the same for the reference control (3 independent WT clones), except for the Fig. 6 experiments that were performed on 2 Trim32 KO and 2 WT clones. All the Western Blots, immunofluorescence, qPCR data are representative of the results of at least 3 independent experiments unless otherwise stated. We reported the number and type of replicates as well as the microscope fields analyzed.

   We repeated the statistical analyses of the data in Figure 5G, EV5D, EV5E, employing more appropriately the 2-way-ANOVA test, as suggested, and we now reported this info in the graphs and legends.

   We thank the Reviewer for raising this point, we agree and substituted the graphs in Fig. EV5B and 6B showing the control values normalised as suggested. The statistical analyses now reflect this change.

   -Some English mistakes require additional read-throughs. For example: "Indeed, Trim32 has no effect on the stability of c-Myc mRNA in proliferating conditions, but upon induction of differentiation the stability of c-Myc mRNA resulted enhanced in Trim32 KO clones (Fig. 5G, Fig. EV5D and 5E)."

   Authors’ response. We re-edited this revised version of the manuscript as suggested.

   -Results in Figure 5A should be quantified

   Authors’ response. We amended this point by quantifying the results shown in Fig. 5A, we added the graph of the quantification of 3 experimental replicates to the Figure. Quantification confirms that no statistically significant difference is observed. The Figure and the relative legend are modified accordingly.

   -Based on the nuclear marker p84, the separation of cytoplasmic and nuclear fractions is not ideal in Figure 5D

   Authors’ response. We agree with the Reviewer that the presence of p84 also in the cytoplasmic fraction is not ideal. Regrettably, we observed this faint p84 band in all the experiments performed. We think however, that this is not impacting on the result that clearly shows that c-Myc and Trim32 are never detected in the same compartment.

   -In Figure 6, it is not appropriate to perform statistical analyses on only two data points per condition.

   Authors’ response. We agree with the Reviewer and we now show the graph of the results of the 3 technical replicates for 2 biological replicates and do not indicate any statistics (Fig. 6B). The graph was also modified according to a previous point raised.

   -The nuclear MYOG phenotype is very interesting; could this be related to requirements of TRIM32 in fusion?

   Authors’ response. We agree with the Reviewer that Trim32 might also be necessary for myoblast fusion. This point is however beyond the scope of the present study and will be addressed in future work.

   - The hypothesis that TRIM32 destabilizes c-Myc mRNA is intriguing but requires stronger mechanistic support. This would be more convincing with RNA immunoprecipitation to test direct association with c-Myc mRNA, and/or co-immunoprecipitation to identify interactions between TRIM32 and proteins involved in mRNA stability. The study would also be strengthened by reporter assays, such as c-Myc 3′UTR luciferase constructs in WT and KO cells, to directly demonstrate 3′UTR-dependent regulation of mRNA stability.

   Authors’ response. This point will be addressed as detailed in the Revision Plan

   Reviewer #3 (Significance (Required)):

   The manuscript presents a minor conceptual advance in understanding TRIM32 function in myogenic differentiation. Its main limitation is that all experiments were performed in C2C12 cells. While C2C12 are a classical system to study muscle differentiation, they are an immortalized, long-cultured, and genetically unstable line that represents a committed myoblast stage rather than bona fide satellite cells. They therefore do not fully model the biology of early regenerative responses. Several TRIM32 phenotypes reported in the literature differ between primary satellite cells and cell lines, and the authors themselves note such discrepancies. Extrapolating these findings to LGMDR8 pathogenesis without validation in primary human myoblasts, satellite cell assays, or in vivo regeneration models is therefore not justified. Previous work has already established clear roles for TRIM32 in mouse satellite cells in vivo and in patient myoblasts in vitro, whereas this study introduces a novel link to c-Myc regulation during differentiation. In addition, without mechanistic evidence, the central claim that TRIM32 regulates c-Myc mRNA stability remains descriptive and incomplete. Nevertheless, the results will be of interest to researchers studying LGMD and to those exploring TRIM32 biology in broader contexts. I review this manuscript as a muscle biologist with expertise in satellite cell biology and transcriptional regulation.

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Reply to the Reviewers

   I thank the Referees for their...

   Referee #1

   1. The authors should provide more information when...

   Responses

   • The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A).
   • Though this is not stated in the MS

   1. Figure 6: Why has only...

   Response: We expanded the comparison

   Minor comments:

   1. The text contains several...

   Response: We added...

   Referee #2

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Reply to the Reviewers

   I thank the Referees for their...

   Referee #1

   1. The authors should provide more information when...

   Responses

   • The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A).
   • Though this is not stated in the MS

   1. Figure 6: Why has only...

   Response: We expanded the comparison

   Minor comments:

   1. The text contains several...

   Response: We added...

   Referee #2

   Read the original source
6. 

   Review Commons

   Nov 4, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #3

   Evidence, reproducibility and clarity

   In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. …

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #3

   Evidence, reproducibility and clarity

   In this paper, the authors examine the role of TRIM32, implicated in limb girdle muscular dystrophy recessive 8 (LGMDR8), in the differentiation of C2C12 mouse myoblasts. Using CRISPR, they generate mutant and wild-type clones and compare their differentiation capacity in vitro. They report that Trim32-deficient clones exhibit delayed and defective myogenic differentiation. RNA-seq analysis reveals widespread changes in gene expression, although few are validated by independent methods. Notably, Trim32 mutant cells maintain residual proliferation under differentiation conditions, apparently due to a failure to downregulate c-Myc. Translation inhibition experiments suggest that TRIM32 promotes c-Myc mRNA destabilization, but this conclusion is insufficiently substantiated. The authors also perform rescue experiments, showing that c-Myc knockdown in Trim32-deficient cells alleviates some differentiation defects. However, this rescue is not quantified, was conducted in only two of the three knockout lines, and is supported by inappropriate statistical analysis of gene expression. Overall, the manuscript in its current form has substantial weaknesses that preclude publication. Beyond statistical issues, the major concerns are: (1) exclusive reliance on the immortalized C2C12 line, with no validation in primary/satellite cells or in vivo, (2) insufficient mechanistic evidence that TRIM32 acts directly on c-Myc mRNA, and (3) overinterpretation of disease relevance in the absence of supporting patient or in vivo data. Please find more details below:

   • TRIM32 complementation / rescue experiments to exclude clonal or off-target CRISPR effects and show specificity are lacking.
   • The authors link their in vitro findings to LGMDR8 pathogenesis and propose that the Trim32-c-Myc axis may serve as a central regulator of muscle regeneration in the disease. However, LGMDR8 is a complex disorder, and connecting muscle wasting in patients to differentiation assays in C2C12 cells is difficult to justify. No direct evidence is provided that the proposed mRNA mechanism operates in patient-derived samples or in mouse satellite cells. Moreover, the partial rescue achieved by c-Myc knockdown (which does not fully restore myotube morphology or differentiation index) further suggests that the disease connection is not straightforward. Validation of the TRIM32-c-Myc axis in a physiologically relevant system, such as LGMD patient myoblasts or Trim32 mutant mouse cells, would greatly strengthen the claim. -Some gene expression changes from the RNA-seq study in Figure 2 should be validated by qPCR
   • The paper shows siRNA knockdown of c-Myc in KO restores Myogenin RNA/protein but does not fully rescue myotube morphology or differentiation index. This suggests that Trim32 controls additional effectors beyond c-Myc; yet the authors do not pursue other candidate mediators identified in the RNA-seq. The manuscript would be strengthened by systematically testing whether other deregulated transcripts contribute to the phenotype.
   • There are concerns with experimental/statistical issues and insufficient replicate reporting. The authors use unpaired two-tailed Student's t-test across many comparisons; multiple testing corrections or ANOVA where appropriate should be used. In Figure EV5B and Figure 6B, the authors perform statistical analyses with control values set to 1. This method masks the inherent variability between experiments and artificially augments p values. Control sample values need to be normalized to one another to have reliable statistical analysis. Myotube morphology and differentiation index quantifications need clear description of fields counted, blind analysis, and number of biological replicates. -Some English mistakes require additional read-throughs. For example: "Indeed, Trim32 has no effect on the stability of c-Myc mRNA in proliferating conditions, but upon induction of differentiation the stability of c-Myc mRNA resulted enhanced in Trim32 KO clones (Fig. 5G, Fig. EV5D and 5E)." -Results in Figure 5A should be quantified -Based on the nuclear marker p84, the separation of cytoplasmic and nuclear fractions is not ideal in Figure 5D -In Figure 6, it is not appropriate to perform statistical analyses on only two data points per condition. -The nuclear MYOG phenotype is very interesting; could this be related to requirements of TRIM32 in fusion?
   • The hypothesis that TRIM32 destabilizes c-Myc mRNA is intriguing but requires stronger mechanistic support. This would be more convincing with RNA immunoprecipitation to test direct association with c-Myc mRNA, and/or co-immunoprecipitation to identify interactions between TRIM32 and proteins involved in mRNA stability. The study would also be strengthened by reporter assays, such as c-Myc 3′UTR luciferase constructs in WT and KO cells, to directly demonstrate 3′UTR-dependent regulation of mRNA stability.

   Significance

   The manuscript presents a minor conceptual advance in understanding TRIM32 function in myogenic differentiation. Its main limitation is that all experiments were performed in C2C12 cells. While C2C12 are a classical system to study muscle differentiation, they are an immortalized, long-cultured, and genetically unstable line that represents a committed myoblast stage rather than bona fide satellite cells. They therefore do not fully model the biology of early regenerative responses. Several TRIM32 phenotypes reported in the literature differ between primary satellite cells and cell lines, and the authors themselves note such discrepancies. Extrapolating these findings to LGMDR8 pathogenesis without validation in primary human myoblasts, satellite cell assays, or in vivo regeneration models is therefore not justified. Previous work has already established clear roles for TRIM32 in mouse satellite cells in vivo and in patient myoblasts in vitro, whereas this study introduces a novel link to c-Myc regulation during differentiation. In addition, without mechanistic evidence, the central claim that TRIM32 regulates c-Myc mRNA stability remains descriptive and incomplete. Nevertheless, the results will be of interest to researchers studying LGMD and to those exploring TRIM32 biology in broader contexts. I review this manuscript as a muscle biologist with expertise in satellite cell biology and transcriptional regulation.

   Read the original source
7. 

   Review Commons

   Nov 4, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #2

   Evidence, reproducibility and clarity

   Summary:

   In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic …

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #2

   Evidence, reproducibility and clarity

   Summary:

   In this study, the authors sought to investigate the molecular role of Trim32, a tripartite motif-containing E3 ubiquitin ligase often associated with its dysregulation in Limb-Girdle Muscular Dystrophy Recessive 8 (LGMDR8), and its role in the dynamics of skeletal muscle differentiation. Using a CRISPR-Cas9 model of Trim32 knockout in C2C12 murine myoblasts, the authors demonstrate that loss of Trim32 alters the myogenic process, particularly by impairing the transition from proliferation to differentiation. The authors provide evidence in the way of transcriptomic profiling that displays an alteration of myogenic signaling in the Trim32 KO cells, leading to a disruption of myotube formation in-vitro. Interestingly, while previous studies have focused on Trim32's role in protein ubiquitination and degradation of c-Myc, the authors provide evidence that Trim32-regulation of c-Myc occurs at the level of mRNA stability. The authors show that the sustained c-Myc expression in Trim32 knockout cells disrupts the timely expression of key myogenic factors and interferes with critical withdrawal of myoblasts from the cell cycle required for myotube formation. Overall, the study offers a new insight into how Trim32 regulates early myogenic progression and highlights a potential therapeutic target for addressing the defects in muscular regeneration observed in LGMDR8.

   Major Comments:

   The work is a bit incremental based on this: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030445 And this: https://www.nature.com/articles/s41418-018-0129-0 To their credit, the authors do cite the above papers.

   The authors do provide compelling evidence that Trim32 deficiency disrupts C2C12 myogenic differentiation and sustained c-Myc expression contributes to this defective process. However, while knockdown of c-Myc does restore Myogenin levels, it was not sufficient to normalize myotube morphology or differentiation index, suggesting an incomplete picture of the Trim32-dependent pathways involved. The authors should qualify their claim by emphasizing that c-Myc regulation is a major, but not exclusive, mechanism underlying the observed defects. This will prevent an overgeneralization and better align the conclusions with the author's data. The authors provide a thorough and well-executed interrogation of cell cycle dynamics in Trim32 KO clones, combining phosphor-histone H3 flow cytometry of DNA content, and CFSE proliferation assays. These complementary approaches convincingly show that, while proliferation states remain similar in WT and KO cells, Trim32-deficient myoblasts fail in their normal withdraw from the cell cycle during exposure to differentiation-inducing conditions. This work adds clarity to a previously inconsistent literature and greatly strengthens the study.

   The transcriptomic analysis (detailed In the "Transcriptomic analysis of Trim32 WT and KO clones along early differentiation" section of Results) is central to the manuscript and provides strong evidence that Trim32 deficiency disrupts normal differentiation processes. However, the description of the pathway enrichment results is highly detailed and somewhat compressed, which may make it challenging for readers to following the key biological 'take-homes'. The narrative quickly moves across their multiple analyses like MDS, clustering, heatmaps, and bubble plots without pausing to guide the reader through what each analysis contributes to the overall biological interpretation. As a result, the key findings (reduced muscle development pathways in KO cells and enrichment of cell cycle-related pathways) can feel somewhat muted. The authors may consider reorganizing this section, so the primary biological insights are highlighted and supported by each of their analyses. This would allow the biological implications to be more accessible to a broader readership.

   The work would be greatly strengthened by the conclusion of LGMDR8 primary cells, and rescue experiments of TRIM32 to explore myogenesis. Also, EU (5-ethynyl uridine) pulse-chase experiments to label nascent and stable RNA coupled with MYC pulldowns and qPCR (or RNA-sequencing of both pools) would further enhance the claim that MYC stability is being affected.

   "On one side, c-Myc may influence early stages of myogenesis, such as myoblast proliferation and initial myotube formation, but it may not contribute significantly to later events such as myotube hypertrophy or fusion between existing myotubes and myocytes. This hypothesis is supported by recent work showing that c-Myc is dispensable for muscle fiber hypertrophy but essential for normal MuSC function (Ham et al, 2025)." Also address and discuss the following, as what is currently written is not entirely accurate: https://www.embopress.org/doi/full/10.1038/s44319-024-00299-z and https://journals.physiology.org/doi/prev/20250724-aop/abs/10.1152/ajpcell.00528.2025

   Minor Comments:

   Z-score scale used in the pathway bubble plot (Figure 2C) could benefit from alternative color choices. Current gradient is a bit muddy and clarity for the reader could be improved by more distinct color options, particularly in the transition from positive to negative Z-score.

   Clarification on the rationale for selecting the "top 18" pathways would be helpful, as it is not clear if this cutoff was chosen arbitrarily or reflects a specific statistical or biological threshold.

   The authors alternates between using "Trim 32 KO clones" and "KO clones" throughout the manuscript. Consistent terminology across figures and text would improve readability.

   Cell culture methodology does not specify passage number or culture duration (only "At confluence") before differentiation. This is important, as C2C12 differentiation potential can drift with extended passaging.

   Significance

   General Assessment:

   This study provides a thorough investigation of Trim32's role the processes related to skeletal muscle differentiation using a CRISPR-Cas9 knockout C2C12 model. The strengths of this study lie in the multi-layered experimental approach as the authors incorporated transcriptomics, cell cycle profiling, and stability assays which collectively build a strong case for their hypothesis that Trim32 is a key factor in the normal regulation of myogenesis. The work is also strengthened by the use of multiple biological and technical replicates, particularly the independent KO clones which helps address potential clonal variation issues that could occur. The largest limitation to this study is that, while the c-Myc mechanism is well explored, the other Trim32-dependent pathways associated with the disruption (implicated by the incomplete rescue by c-Myc knockdown) are not as well addressed. Overall however, the study convincingly identifies a critical function for Trim32 during skeletal muscle differentiation.

   Advance:

   To my knowledge, this is the first study to demonstrate the mRNA stability level of c-Myc regulation by Trim32, rather than through the ubiquitin-mediated protein degradation. This work will advance the current understanding and provide a more complete understanding of Trim32's role in c-Myc regulation. Beyond c-Myc, this work highlights the idea that TRIM family proteins can influence RNA stability which could implicate a broader role in RNA biology and has potential for future therapeutic targeting.

   Audience:

   This research will be of interest to an audience that focuses on broad skeletal muscle biology but primarily to readers with more focused research such as myogenesis and neuromuscular disease (LGMDR8 in particular) where the defined Trim32 governance over early differentiation checkpoints will be of interest. It will also provide mechanistic insights to those outside of skeletal muscle that study TRIM family proteins, ubiquitin biology, and RNA regulation. For translational/clinical researchers, it identifies the Trim32/c-Myc axis as a potential therapeutic target for LGMDR8 and related muscular dystrophies.

   Expertise:

   My expertise lies in skeletal muscle biology, gene editing, transgenic mouse models, and bioinformatics. I feel confident evaluating the data and conclusions as presented.

   Read the original source
8. 

   Review Commons

   Nov 4, 2025

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #1

   Evidence, reproducibility and clarity

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases. In my opinion, a few aspects would improve the manuscript.

   Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studi…

   Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

   Learn more at Review Commons

   ---

   Referee #1

   Evidence, reproducibility and clarity

   In this manuscript, Xiong and colleagues investigate the mechanisms operating downstream to TRIM32 and controlling myogenic progression from proliferation to differentiation. Overall, the bulk of the data presented is robust. Although further investigation of specific aspects would make the conclusions more definitive (see below), it is an interesting contribution to the field of scientists studying the molecular basis of muscle diseases. In my opinion, a few aspects would improve the manuscript.

   Firstly, the conclusion that Trim32 regulates c-Myc mRNA stability could be expanded and corroborated by further mechanistic studies:

   1. Studies investigating whether Tim32 binds directly to c-Myc RNA. Moreover, although possibly beyond the scope of this study, an unbiased screening of RNA species binding to Trim32 would be informative.
   2. If possible, studies in which the overexpression of different mutants presenting specific altered functional domains (NHL domain known to bind RNAs and Ring domain reportedly involved in protein ubiquitination) would be used to test if they are capable or incapable of rescuing the reported alteration of Trim32 KO cell lines in c-Myc expression and muscle maturation. An optional aspect that might be interesting to explore is whether the alterations in c-Myc expression observed in C2C12 might be replicated with primary myoblasts or satellite cells devoid of Trim32.

   I also have a few minor points to highlight:

   • It is unclear if the differences highlighted in graphs 5G, EV5D, and EV5E are statistically significant.
   • On page 10, it is stated that c-Myc down-regulation cannot rescue KO myotube morphology fully nor increase the differentiation index significantly, but the corresponding data is not shown. Could the authors include those quantifications in the manuscript?

   Significance

   The manuscript offers several strengths. It provides novel mechanistic insight by identifying a previously unrecognized role for Trim32 in regulating c-Myc mRNA stability during the onset of myogenic differentiation. The study is supported by a robust methodology that integrates CRISPR/Cas9 gene editing, transcriptomic profiling, flow cytometry, biochemical assays, and rescue experiments using siRNA knockdown. Furthermore, the work has a disease relevance, as it uncovers a mechanistic link between Trim32 deficiency and impaired myogenesis, with implications for the pathogenesis of LGMDR8. At the same time, the study has some limitations. The findings rely exclusively on the C2C12 myoblast cell line, which may not fully represent primary satellite cell or in vivo biology. The functional rescue achieved through c-Myc knockdown is only partial, restoring Myogenin expression but not the full differentiation index or morphology, indicating that additional mechanisms are likely involved. Although evidence supports a role for Trim32 in mRNA destabilization, the precise molecular partners-such as RNA-binding activity, microRNA involvement, or ligase function-remain undefined. Some discrepancies with previous studies, including Trim32-mediated protein degradation of c-Myc, are acknowledged but not experimentally resolved. Moreover, functional validation in animal models or patient-derived cells is currently lacking.

   Despite these limitations, the study represents an advancement for the field. It shifts the conceptual framework from Trim32's canonical role in protein ubiquitination to a novel function in RNA regulation during myogenesis. It also raises potential clinical implications by suggesting that targeting the Trim32-c-Myc axis, or modulating c-Myc stability, may represent a therapeutic strategy for LGMDR8. This work will be of particular interest to muscle biology researchers studying myogenesis and the molecular basis of muscle disease, RNA biology specialists investigating post-transcriptional regulation and mRNA stability, and neuromuscular disease researchers and clinicians seeking to identify new molecular targets for therapeutic intervention in LGMDR8.

   The Reviewer expressing this opinion is an expert in muscle stem cells, muscle regeneration, and muscle development.

   Read the original source
9. 

   Version published to 10.1101/2025.06.25.661523 on bioRxiv

   Jun 27, 2025